ProCE Banner Activity

Considerations From Experts on Optimal Use of Immunotherapy for Patients With Lung Cancer

Clinical Thought
Gain expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC.

Released: January 23, 2023

Expiration: January 22, 2024

Share

Faculty

Julie Brahmer

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Jarushka Naidoo

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Zofia Piotrowska

Zofia Piotrowska, MD, MHS

Assistant Professor
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Regeneron Pharmaceuticals, Inc.

Program Director Disclosure

Program Director

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Julie R. Brahmer, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Janssen, Lilly, Merck, Regeneron, Sanofi.

Faculty Disclosure

Primary Author

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Jarushka Naidoo, MB, BCH, MHS: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Kaleido Biosciences, Merck, NGM Pharmaceuticals, Novartis, Pfizer, Roche/Genentech, Takeda; researcher: Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, Mirati, Novartis, Roche/Genentech.

Zofia Piotrowska, MD, MHS

Assistant Professor
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: consultant/advisor/speaker: AstraZeneca, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo, Janssen, Lilly, Takeda; researcher: AbbVie, AstraZeneca, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, Tesaro/GlaxoSmithKline.